Danielle Miller - Abcam Plc Operations Director
ABCZF Stock | USD 22.25 0.00 0.00% |
Director
Ms. Danielle Miller Ph.D. is Operations Director of Abcam Plc. Danielle joined Abcam in 2001 and over the last 14 years has overseen the growth in logistics and stock management capabilities championing investment in automated stock storage solutions and optimising the split of stock across Abcams four logistics hubs in Cambridge UK and US Shanghai and Tokyo. She works closely with the regional offices to drive consistency and efficiency of operational processes to ensure that customers can expect similar high levels of service across the world. Her role also involves overseeing health and safety and employee wellbeing and she is passionate about ensuring that our sites meet required global standards. Prior to joining Abcam Danielle worked as a strategic management consultant. since 2013.
Tenure | 11 years |
Phone | 44 12 2369 6000 |
Web | https://www.abcam.com |
Abcam Plc Management Efficiency
The company has return on total asset (ROA) of 0.0326 % which means that it generated a profit of $0.0326 on every $100 spent on assets. This is way below average. Abcam Plc's management efficiency ratios could be used to measure how well Abcam Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Kevin Lorenz | Fortress Biotech Pref | N/A | |
Malcolm Hoenlein | Fortress Biotech Pref | 73 | |
Bruno Angelici | Novo Nordisk AS | 68 | |
Peter Kiener | GT Biopharma | 63 | |
Mette Jensen | Novo Nordisk AS | 45 | |
Sylvie Gregoire | Novo Nordisk AS | 59 | |
Anne Kverneland | Novo Nordisk AS | 64 | |
Thomas Rantzau | Novo Nordisk AS | 46 | |
Kasim Kutay | Novo Nordisk AS | 55 | |
John Bonfiglio | GT Biopharma | 60 | |
Soeren Pedersen | Novo Nordisk AS | 52 | |
Liselotte Hyveled | Novo Nordisk AS | 51 | |
Jimmie Harvey | Fortress Biotech Pref | 62 | |
David Barrett | Fortress Biotech Pref | 39 | |
Stig Stroebaek | Novo Nordisk AS | 55 | |
Martin Mackay | Novo Nordisk AS | 64 | |
Laurence Debroux | Novo Nordisk AS | 51 | |
Liz Hewitt | Novo Nordisk AS | 64 | |
Brian Daniels | Novo Nordisk AS | 61 | |
Geoffrey Davis | GT Biopharma | N/A | |
Eivind Kolding | Novo Nordisk AS | 55 |
Management Performance
Return On Equity | 0.0069 | |||
Return On Asset | 0.0326 |
Abcam plc Leadership Team
Elected by the shareholders, the Abcam Plc's board of directors comprises two types of representatives: Abcam Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abcam. The board's role is to monitor Abcam Plc's management team and ensure that shareholders' interests are well served. Abcam Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abcam Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Bushfield, Scientific Director | ||
Peter Allen, Non-Executive Chairman of the Board | ||
Suzanne Smith, Chief Legal Officer, Company Secretary | ||
Murray Hennessy, Non-Executive Independent Director | ||
Matthew Roe, Head of Reagents | ||
Marc Perkins, Interim Company Secretary | ||
Gavin Wood, CFO - Elect | ||
Nick Skinner, VP HR | ||
Louise Patten, Independent Non-Executive Director | ||
Jane Cooke, Corporate Services Director | ||
Jim Warwick, COO, Executive Director | ||
Danielle Miller, Operations Director | ||
Alejandra Solache, Head - Reagents Product Development and Manufacturing | ||
Yvonne Chien, Chief Digital Officer | ||
Kirstie BBusSc, Head Insights | ||
Philippe Cotrel, Commercial Director | ||
Emma Sceats, Service Sales | ||
Alan Hirzel, CEO and Director | ||
Jeffrey Iliffe, CFO, Executive Director | ||
Kirstie Speck, Head of Consumer Insights | ||
Anthony Martin, Non-Executive Independent Director | ||
Giles Kerr, Non-Executive Director | ||
Mark Dermody, Interim CIO | ||
Jonathan Milner, Co-Founder and Non-Executive Deputy Chairman | ||
Michael BA, CFO Director | ||
Sean Hickey, CIO | ||
Susan Harris, Non-Executive Director | ||
James Staveley, Vice President - Investor Relations | ||
Michael Ross, Non-Executive Independent Director | ||
BS MBA, CEO Director | ||
Mara Aspinall, Non-Executive Director |
Abcam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Abcam Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0069 | |||
Return On Asset | 0.0326 | |||
Profit Margin | 0.02 % | |||
Operating Margin | 0.15 % | |||
Current Valuation | 3.69 B | |||
Shares Outstanding | 229.27 M | |||
Shares Owned By Insiders | 16.20 % | |||
Shares Owned By Institutions | 66.10 % | |||
Price To Earning | 199.38 X | |||
Price To Book | 3.96 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abcam Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abcam Plc's short interest history, or implied volatility extrapolated from Abcam Plc options trading.
Pair Trading with Abcam Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abcam Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abcam Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Abcam Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abcam Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abcam Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abcam plc to buy it.
The correlation of Abcam Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abcam Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abcam plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abcam Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcam plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Abcam plc information on this page should be used as a complementary analysis to other Abcam Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Abcam Pink Sheet analysis
When running Abcam Plc's price analysis, check to measure Abcam Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcam Plc is operating at the current time. Most of Abcam Plc's value examination focuses on studying past and present price action to predict the probability of Abcam Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abcam Plc's price. Additionally, you may evaluate how the addition of Abcam Plc to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |